OKYO Pharma Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Quarter	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Jun '24 Jun 30, 2024	Mar '24 Mar 31, 2024	Dec '23 Dec 31, 2023
Cost of Revenue	6.69	6.48	6.26	5.55	4.84	4.67	4.49	6	7.51	7.79
Gross Profit	-6.69	-6.48	-6.26	-5.55	-4.84	-4.67	-4.49	-6	-7.51	-7.79
Research & Development	1.81	0.9	-0.01	1.12	2.25	4.06	5.86	7.05	8.24	8.3
Operating Expenses	1.81	0.9	-0.01	1.12	2.25	4.06	5.86	7.05	8.24	8.3
Operating Income	-8.5	-7.38	-6.25	-6.67	-7.09	-8.72	-10.35	-13.05	-15.75	-16.09
Interest Expense	-0.47	-0.34	-0.2	-0.53	-0.87	-1.34	-1.81	-1.43	-1.05	-0.58
Interest & Investment Income	0.03	0.02	0.01	0.01	0.01	0	-	-	-	-
Other Non Operating Income (Expenses)	-0	-0.01	-0.01	-0.01	-0.01	-0.01	-	-	-	-
EBT Excluding Unusual Items	-8.94	-7.7	-6.46	-7.21	-7.97	-10.07	-12.17	-14.48	-16.8	-16.67
Pretax Income	-8.94	-7.7	-6.46	-7.21	-7.97	-10.07	-12.17	-14.48	-16.8	-16.67
Income Tax Expense	0.01	-0.92	-1.85	-2.55	-3.26	-2.37	-1.48	-0.73	0.02	0.05
Earnings From Continuing Operations	-8.95	-6.78	-4.61	-4.66	-4.71	-7.7	-10.69	-13.76	-16.83	-16.71
Net Income	-8.95	-6.78	-4.61	-4.66	-4.71	-7.7	-10.69	-13.76	-16.83	-16.71
Net Income to Common	-8.95	-6.78	-4.61	-4.66	-4.71	-7.7	-10.69	-13.76	-16.83	-16.71
Net Income Growth (YoY)	-	-	-	-	-	-	-	-	-	-
Shares Outstanding (Basic)	37	39	41	40	39	36	33	31	29	27
Shares Outstanding (Diluted)	37	39	41	40	39	36	33	31	29	27
Shares Change (YoY)	-5.40%	8.26%	24.46%	29.20%	34.57%	35.66%	36.97%	34.52%	-	-
EPS (Basic)	-0.24	-0.17	-0.11	-0.12	-0.12	-0.21	-0.32	-0.44	-0.57	-0.62
EPS (Diluted)	-0.24	-0.17	-0.11	-0.12	-0.12	-0.21	-0.32	-0.44	-0.57	-0.62
EPS Growth (YoY)	-	-	-	-	-	-	-	-	-	-

Additional Metrics

Fiscal Quarter	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Jun '24 Jun 30, 2024	Mar '24 Mar 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-5.94	-4.52	-3.1	-2.46	-1.81	-2.38	-2.94	-6.21	-9.49	-10.24
Free Cash Flow Per Share	-0.16	-0.12	-0.07	-0.06	-0.05	-0.07	-0.09	-0.20	-0.32	-0.38
EBITDA	-8.5	-7.38	-6.25	-6.67	-7.09	-8.72	-10.35	-13.05	-15.75	-16.09
D&A For EBITDA	0	0	0	0	0	0	0	0	0	0
EBIT	-8.5	-7.38	-6.25	-6.67	-7.09	-8.72	-10.35	-13.05	-15.75	-16.09

SEC Filings: 10-K · 10-Q